A Snapshot of IPF Care in Europe

An EU-IPFF benchmarking report on access to Idiopathic Pulmonary Fibrosis (IPF) care in Europe
The content of the Benchmarking Report represents the views of the authors only and is their sole responsibility. The 2020 Benchmarking Report is the second edition, and includes four additional countries in the analysis.

This Report is not intended as an exhaustive or scientific review of the care and management of IPF in Europe. The interviews on which this Report is based have provided useful insights into some of the issues affecting a selection of patients living with IPF and their families. They also supported the identification of several discrepancies in IPF care within and between European countries.

Recognising that the Benchmarking Report only represents a snapshot of the IPF landscape in seventeen EU countries, the EU-IPFF welcomes feedback.

For more information or to share any concerns or comments you may have, please contact: secretariat@eu-ipff.org

The EU-IPFF remembers Harry van der Haak and Maria Rigo who sadly passed away while we were working on this update. Their comments remain within the report with our gratitude for their inspiring advocacy work on behalf of their patient communities in Netherlands and Hungary.

Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche LTD and Galapagos NV financially supported the Benchmarking Report.

Last updated: November 2020
Foreword from the EU-IPFF president

Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-term disease that affects the lungs. To be diagnosed with the disease is devastating. Over time, people living with IPF become more and more breathless and often suffer from a debilitating cough. In time, they will need supplementary oxygen and ultimately die from respiratory failure. Currently, there is no cure for IPF and many patients only survive two to five years after diagnosis. As a serious and progressive disease, IPF places a significant social, physical and emotional burden on patients’ lives.

For many years, national IPF patient organisations have joined forces to drive policy change for IPF care in Europe. Supportive research and development frameworks in rare diseases, such as the European regulation on orphan medicines (1999), have created opportunities for industry to invest in disease areas with high unmet needs and provide treatment options that were not available 10 years ago. However, access to IPF treatment and care remains unequal between and within countries. This gap in care has been further exacerbated by the recent COVID-19 pandemic. At the beginning of the outbreak, patients across Europe were not recognized as at risk, which amplified the lack of recognition for those battling the severe pulmonary disease.

For many years, national IPF patient organisations have joined forces to drive policy change for IPF and rare diseases. Through this collaboration we published the European IPF Patient Charter and our efforts led to the adoption of a Written Declaration from MEP Cristian Buşoi on IPF by the European Parliament. In 2016, the European Federation on Idiopathic Pulmonary Fibrosis & Related Disorders Federation (EU-IPFF) was formally established with the objective to improve the care and quality of life of people living with IPF across Europe.

To paint a picture of the current situation of IPF care in Europe, EU-IPFF has developed a Benchmarking Report to identify gaps in care, compare countries’ performances and encourage the replication of best practices. The first version covered 13 countries and we have expanded the second edition to include four additional countries. The updated Report is a major achievement for our community.

In times of great uncertainty, our national organisations offset the disruption of healthcare services. In response to the cancellation of elective procedures, such as lung transplants and routine consultations, patients that experienced high levels of stress were provided with psychological support. The COVID-19 pandemic has reiterating the importance of our work, as it has brought to the fore the need to redesign healthcare services to ensure better preparedness and protection of people at-risk.

This involves the improvement of information to those living with rare lung disease, through the specialised care needed for patients, and eliminating inequalities in access to treatment.

The Benchmarking Report comes with concrete recommendations on how patient care can be improved both for those living with IPF and their families. The healthcare sector is currently experiencing a high level of political attention. We believe we have a unique opportunity to make a significant change in IPF care, and our ambition is to build a more resilient European healthcare system. We hope that the updated Benchmarking Report can make a contribution towards this goal and influence healthcare decisions to ensure that every patient has an equal opportunity to access quality information and care.

Steve Jones
EU-IPFF President
November 2020

Foreword from MEP Cristian Buşoi

Chair of the European Parliament’s Committee on Industry, Research and Energy
Rapporteur of the European Parliament for the EU4Health Programme 2021-2027

The COVID-19 crisis has clearly proven the European Union’s need for well-defined and adequately-financed policy instruments, and has revealed the shortcomings and inefficiencies in our health systems. It has also, unfortunately, deepened the gap in diagnosis and access to care, underlining once more the importance of addressing the lack of proper treatment. Moreover, COVID-19 has highlighted the need for boosting innovation and investing more in health in general.

Non-communicable and rare diseases, including respiratory conditions such as IPF, constitute a major public health challenge and need to be a priority under the next health programme. Given the nature of IPF, which is a condition affecting mainly people over 65 years old, more needs to be done to protect this already at-risk group, especially in pandemic times and health crises. This can be achieved by streamlining specific measures and specific guidelines with tailor-made recommendations.

Moreover, in order to reduce inequalities between countries in relation to access to accurate diagnoses of rare diseases, pharmaceutical and non-pharmaceutical treatments have to be urgently addressed. It is no longer acceptable that in 2020, the overall assessment of care in the EU12 countries is more negative than in the other Member States. All EU national governments must ensure that health and social care systems are inclusive of the needs of people living with a rare disease, such as IPF.

It is also essential that governments recognize patient organisations’ roles in providing accurate information and peer support to patients in need, as well as advocating for research activities and studies that provide significant evidence on existing gaps in diagnosis and care.

Nevertheless, the next Multiannual Financial Framework will carve out more funding opportunities under the Horizon Europe instrument and the EU4Health Programme that will bring an added value in the field of health, making our health systems resilient for future health threats and challenges. This will be of great benefit as it will also contribute to increasing the ability of health systems to face the realities of the moment like shortages, fragmented access to treatment, lack of new antibiotics and innovative treatments, and last, but not least, it should boost the health sector towards digitalisation.

Finally, I would like to congratulate EU-IPFF for this informative and comprehensive report! We can definitely make a tangible difference in the lives of patients with IPF, if all relevant stakeholders in the healthcare space join forces and continue to advance positive changes.

MEP Cristian Buşoi
(EPP, Romania)
Rationale

With a view to driving evidence-based policies, the European Idiopathic Pulmonary Fibrosis & Related Disorders Federation (EU-IPFF) commissioned a first edition of the Benchmarking Report in 2018. Its goal was to measure how European countries, where EU-IPFF members are based, were performing against a number of criteria related to IPF care and management. A new edition of the report (2020) is now available and includes four additional countries. The Report highlights best practices and identifies gaps where urgent policy action is needed.

The Benchmarking Report aims to:

• Collect qualitative information about IPF patient care in Europe in order to compare the situation of patients between countries;
• Identify gaps in IPF care in Europe;
• Identify best practices in IPF care across Europe;
• Make recommendations for solutions that could improve IPF care and the overall quality of life of people living with IPF.

Methodology

A qualitative study was designed to collect data from 19 patient organisations from 17 EU Member States. This new version includes four additional countries in the analysis compared to the first edition (2018). A structured questionnaire developed in collaboration with medical experts and patient representatives was used for phone interviews and included both closed and open-ended questions focused on the following areas:

• Information about the disease;
• Diagnosis and access to specialised care;
• Access to pharmacological and non-pharmacological treatment;
• Access to palliative care and end-of-life care.

EU-IPFF member organisations and partners were invited to take part in phone interviews pending written consent. Each patient organisation had the opportunity to identify the most suitable representative for the 60 to 90 minute interview. The interview results fed into a country scorecard illustrating the country’s performance against specific indicators. The results were analysed using a point-based system: each answer was assigned a colour code based on the level of progress and implementation [see below]. A detailed matrix was developed to support the codification process.

Colour-coding system:

- No existence of policy or development;
- Policy or development exists but implementation has not started yet;
- Policy or development exists and is fully implemented;
- No information available.

The codified answers were shared with interviewees and medical experts for approval and final validation. The findings of all interviews were used to develop a European scorecard that visually compares all the participating countries’ performances against specific indicators.

Acronyms used in the snapshot:

Idiopathic Pulmonary Fibrosis (IPF): a rare, progressive and ultimately fatal pulmonary disease that affects the fragile tissue in the lungs. The cause of IPF is unknown and there is no cure.

Interstitial Lung Diseases (ILDs): a group of disorders characterised by progressive scarring of the lung tissue between and within the air sacs. IPF is an ILD.

ILD Specialised Centres or Centres of Expertise: centres for the management and care of rare disease patients, designated at a national level by each EU Member State. ILD/IPF centres of expertise specialise in ILDs and they aim to provide IPF patients (among others) with the highest standards of care around timely diagnosis, appropriate treatment, and follow-up.

1 Austria, Belgium, Bulgaria, Croatia, Denmark, Finland, France, Germany, Greece, Ireland, Italy, The Netherlands, Poland, Romania, Spain, United Kingdom and Hungary. The questionnaire was translated by a translation agency in the following languages: German, Spanish, French and Italian.
2 The four countries added in the 2020 edition are: Croatia, Denmark, Finland and Romania.
3 The majority of the interviews were conducted in English and five interviews were conducted in the native language spoken by some patient representatives (Italian, French, Romanian and Spanish). Five interviewees preferred to respond to the questionnaire in writing.
4 For one country, the scorecard was developed directly with a medical expert as no patient organisation exists (Denmark).
The Benchmarking Report outlines the current state of IPF care and management in Europe. It identifies best-performing countries along with challenges that require greater political attention and an immediate response. The main highlights, across all countries, are summarised in the table below.

The results of the second edition of the report confirm that no country is performing well across all indicators. This shows that IPF remains an under-prioritised therapeutic area, where urgent policy action is needed to reduce inequalities and barriers to IPF care and management across Europe. Even though there is no absolute best practice, the Benchmarking Report shows a divide between countries reporting a satisfactory performance across most of the indicators, such as in some Western European and Scandinavian countries, and countries presenting a significant number of gaps in IPF care, especially in some Eastern countries.

This edition did not focus on the impact of COVID-19 on IPF care and services, however patients living with IPF have experienced major disruptions in the delivery of routine consultations and elective care, including lung transplantation. This requires further investigation and demonstrates the urgency of addressing existing challenges to ensure better protection and continuity of care for people at-risk, also in times of crisis.

International guidelines on IPF diagnosis and management have been issued by the American Thoracic Society and the European Respiratory Society. National guidelines or position papers have been or are being developed in 12 countries. Patients living with IPF lack access to reliable and comprehensive information. In most countries, information and self-management materials are either limited or not fully integrated into the care process. Newly diagnosed patients with IPF do not always receive supporting information from specialised centres; in the majority of cases, it is up to patient support groups to provide these.

Across all countries, respondents reported that fast and accurate diagnosis is a key barrier to access to care. Delayed diagnosis or misdiagnosis due to challenges in recognising IPF signs and symptoms are frequently cited as key issues. In addition, patient representatives noted slow referral periods, with extended gaps between the initial suspicion of IPF and a confirmed diagnosis.

EMA-approved pharmacological treatments for IPF are available and reimbursed in all surveyed countries. Nearly all of them reported no out-of-pocket costs for patients. However, many respondents deemed the ‘wait-and-watch’ approach to prescribing pharmacological treatment to be a barrier. Prescription rules are another hurdle as the prescription of pharmacological treatment is often restricted to specialised ILD centres or university hospitals. This is compounded by the delays in timely referral to specialised centres.

Respondents underlined the need for non-pharmacological treatment options in order to improve patients’ quality of life. These include oxygen therapy, pulmonary rehabilitation and lung transplantation. Access to these options is very patchy across Europe, as they are either available with restrictions, or, to some extent, unavailable. When available, they are not always fully covered or reimbursed, resulting in out-of-pocket expenses for patients.

Access to palliative care and end-of-life care is extremely fragmented. Some countries have established palliative care centres and teams, while others are only beginning to provide this kind of support. Many respondents also reported that existing end-of-life care programmes are however not specifically designed for patients with IPF.

“"As an IPF patient, I was invited to join a team of expert healthcare professionals to review the German Guidelines on IPF. I strongly felt that I could contribute to this, providing input based on my personal experience. I am particularly satisfied because the concepts of timely access to treatment upon diagnosis, exceptional use of biopsy upon joint doctor-patient decision, and timely referral to a specialised ILD centre were included into the guidelines. I am glad that the patient’s voice was heard during such a process. Patients, alongside with medical experts, are the ones who know best what they need.”

A patient from Germany
Diagnosis and access to specialised care

Key challenge

Early diagnosis remains the main challenge across all countries surveyed.

International guidelines on the diagnosis of IPF were updated in 2018, but are not fully implemented in all countries surveyed. In 10 of the surveyed countries, national guidelines or position papers endorsing international guidelines on IPF diagnosis and care have been adopted. Diagnostic procedures are generally standardised; however, the majority of countries surveyed do not have nationwide IPF diagnostic and care pathways. Instead, these are often established by each expert centre and can therefore vary from region to region.

General practitioners have a limited knowledge of IPF or training in recognising the disease. Its symptoms are therefore sometimes confused with those of other lung diseases. Additionally, genetic testing is not widely performed, not even when another family member has IPF. This further complicates the diagnostic process.

Timely access to specialised centres and multidisciplinary care has been flagged as a factor that can make a real difference for patients. Countries where patients have access to multidisciplinary teams perform better in the diagnostic process, resulting in a better experience for patients. Yet the composition of multidisciplinary teams varies greatly. Many countries, such as Bulgaria and Italy, report shortages or a lack of recognition for specialist lung nurses, who play a crucial role in supporting patients and carers. By contrast, when specialist nurses are available to accompany patients in dealing with their disease every day, as is the case in Denmark, Finland and the UK, positive outcomes are reported.

“Communication with the respiratory physician and with members of the multidisciplinary team is essential in order to get quality information about how to manage IPF in everyday life. After my husband received his IPF diagnosis, we were really worried about what to do next and I did not know how best to support him. In those cases, it has been really essential to interact with the multidisciplinary team and to exchange information with fellow patients in the support group.”

A carer from Austria

“Much remains to be done to improve IPF diagnosis in France. While I was diagnosed fairly quickly, the same cannot be said of my brother. He was misdiagnosed for years, not knowing what his condition was. It is only when I found out that I had IPF and after he shared this information with his doctor that he finally received an accurate diagnosis. We have to do more to ensure that people can be diagnosed in a more timely manner.”

A patient from France

---

7 Available at: [https://www.atsjournals.org/doi/abs/10.1164/rccm.201807-1255ST](https://www.atsjournals.org/doi/abs/10.1164/rccm.201807-1255ST)
Access to pharmacological treatment

Key challenge
Access to treatment in a timely manner following diagnosis is a priority for IPF patients.

There are currently no curative pharmacological treatments for people living with IPF. However, two antifibrotic drugs that can slow down disease progression have been approved by the European Medicines Agency. Although reimbursement criteria for these drugs differ across Europe, these treatments are reimbursed in all surveyed countries. Apart from Finland, none of them reported out-of-pocket costs for patients. However, this is not representative of the wider situation across the EU, since access to and reimbursement of EMA-approved drugs remains a barrier in countries not represented in the EU-IPFF (e.g. Malta).

Despite the availability of EMA-approved treatments, some delays in access remain in practice. This can be due to late diagnosis, clinical inertia (“wait-and-watch” until deterioration of symptoms), national prescription rules, or point-of-care treatment dispensation practices. Overcoming these challenges is vital, since timely access to treatment increases the ability to slow disease progression.

Even when IPF is accurately diagnosed, the “wait-and-watch” attitude is still reported. Some respiratory physicians prefer to monitor the evolution of the disease, postponing treatment initiation. In the UK for instance, antifibrotic treatments can only be prescribed to patients with a lung function of between 80% and 50% of expected Forced Vital Capacity. However, the unpredictable nature of IPF means that a patient’s condition can worsen rapidly: something that the early adoption of antifibrotic treatment could mitigate.

Prescription rules are another significant hurdle. In most countries surveyed, the prescription of pharmacological treatments is restricted to specialised ILD centres (or university hospitals). However, in Austria, France, Germany, Ireland, Romania, Spain and part of the UK (Wales and Scotland) respiratory physicians can also prescribe the treatments. Only in Ireland can general practitioners (GPs) renew antifibrotic treatment prescriptions, with the initial prescription being made by a respiratory physician.

Finally, treatment dispensation and the geographical distribution of centres present further obstacles. In some countries (Belgium, Croatia, Denmark, Italy, Poland and Spain), treatment is only provided through hospital pharmacies or specialised centres. In Greece, only state pharmacies are allowed to dispense pharmacological treatment – but frequent shortages can result in long wait times for patients.

In a majority of countries (Austria, Bulgaria, Finland, France, Germany, Hungary, Ireland, Romania and The Netherlands), treatment can be dispensed by community pharmacies. This should make it easier to access treatment; however, not all community pharmacies have on-site availability of antifibrotic drugs, meaning patients have to order their treatment first before they can collect it. In the UK, community pharmacies offer home delivery, which speeds up access to prescribed treatment. While, in principle, patients in all countries have access to and are reimbursed for antifibrotic treatments, it is clear that there are lingering disparities in the prescription and distribution processes between and within countries. To ensure fast and equal access to treatment, these must be addressed.
Access to non-pharmacological treatment

Key challenge

Access to non-pharmacological treatment options is not homogeneous across Europe.

Non-pharmacological treatment options, such as pulmonary rehabilitation, oxygen therapy, psychological support and lung transplantation are essential for holistic IPF care and to improve patients’ quality of life. Lung transplantation is currently the only curative form of treatment. However, transplantation comes with its own set of challenges: access is limited, there are intrinsic risks associated with the procedure, and of course, there is a limited availability of organs. Oxygen therapy and pulmonary rehabilitation play an essential role in managing IPF but major inequalities persist regarding patient access. Finally, psychological support is often seen as a ‘nice-to-have’, with few hospitals or centres of expertise able to provide such support.

Although lung transplantation is the only existing curative treatment, it is only a viable option for a small number of patients with IPF. There are many barriers to transplantation, such as the patient’s health condition and age, the limited availability of viable organs, and long waiting times. There are specific limitations in some countries, such as Poland and Romania, where there are a limited number of transplantation centres, or in Bulgaria and Greece, which both lack national lung transplantation centres – meaning patients must travel abroad for transplants.

Oxygen therapy at home or in hospital is a common therapeutic option for patients living with IPF. However, disparities exist across Europe. These include: limited access (in Greece, it is only available in the hospital); delayed access; reimbursement issues (in Bulgaria and Poland, oxygen therapy at home is only partially reimbursed or not at all and in Romania, portable oxygen supply devices are not reimbursed); or regional differences (in Ireland reimbursement is not standardised and depends on regional health budgets; in Italy, different regions provide different supply valves for the oxygen concentrators, affecting patients’ in-country mobility). Denmark and the UK are of the few countries that stand out as ambulatory oxygen, and long-term oxygen treatment (LTOT) are available and the operating costs associated with them are fully reimbursed.

As far as pulmonary rehabilitation is concerned, many respondents reported limited availability and reimbursement. In some countries, pulmonary rehabilitation programmes are not specifically designed for patients with IPF.

In Greece, for instance, Patients with IPF do not have access to such programmes – or if available, they are only reimbursed when administered in hospital. Patients from Bulgaria, Finland and Spain mentioned time limitations as their main barrier. In Spain rehabilitation is provided for four months, but it is only provided for ten days in Bulgaria.

Only some countries and regions provide pulmonary rehabilitation at an ambulatory level (e.g. Croatia, France, Ireland and the Bucharest area of Romania), with the majority of countries providing it in-hospital or in specialised centres, which are often far from IPF patients’ homes. The majority of patients with IPF reported a need for access to psychological and emotional support for themselves, their families and their carers. Access to psychological support is currently only available at a local level, through patient support groups. However, this is not systematically available and patients do not always know how to find help.
Access to palliative care and end-of-life care

Key challenge
Palliative care is not offered systematically to European IPF patients.

Access to palliative care and end-of-life care is the most fragmented area across Europe. In principle, it should play a key role in holistic IPF management; however, it is not sufficiently embedded in IPF care and it is not available or reimbursed in all the countries surveyed.

Many respondents explained that palliative care is often confused with end-of-life care, instead of being understood as symptom control and management. This further hinders access, since patients may be deterred from asking for palliative care if they believe it corresponds to end-of-life care. Many respondents also reported that existing end-of-life care programmes are usually focused on cancer patients, with no specific programmes in place for patients with IPF.

In countries where palliative care is offered, patients and their families are involved in the decisions. And when available, palliative care is usually delivered in hospitals and clinics with palliative care units. In some countries (e.g. UK) patients can choose to receive palliative care at home, and only Austria, Denmark and Finland reported the availability of mobile palliative care teams.

Home hospice care is not widely available in Europe; in some countries, such as Bulgaria and Italy, only private hospices exist. Such costs are not reimbursed, which can create a significant financial burden for patients and their families. All surveyed respondents highlighted the importance of a holistic approach to palliative care as part of IPF treatment plans.

“...In countries where the organisation of healthcare services is decentralised, patients often report inequalities in access. This is particularly true in relation to oxygen therapy and palliative care. My hope is that the recommendations of patient and family organisations will be considered to ensure fair and equal access to quality care and support for IPF patients and caregivers across Europe.”

A patient representative from Italy
People living with Idiopathic Pulmonary Fibrosis need to overcome major hurdles during their care journey. Challenges currently occur at all stages. These include diagnostic delays, lack of available treatments and cure, and difficulty in accessing appropriate health services. As a result, patients, their families and carers feel isolated, unsupported and economically curtailed.

This Report seeks to provide a broad picture of the IPF care pathway across 17 EU countries, identifying best practices as well as important gaps in IPF care and management. Although the results may not reflect the whole European situation, they confirm that IPF remains an under-prioritised therapeutic area where urgent policy commitment is required in order to reduce health inequalities and improve the life of patients living with IPF.

Unfortunately, the Report confirms that no country excels on all indicators. All the countries surveyed need to take concrete action to ensure faster and equitable access to high quality IPF care and management throughout the patient journey.

This second edition of the Report confirms that there are alarming variations in access to IPF care and management across European countries. In order to improve care pathways and reduce inequality across Europe, best-practices need to be shared among countries. As a first step, international and national guidelines should be implemented to help standardise care pathways and improve access to specialised care.

Action should also be taken at the primary care level, in order to increase awareness of the early signs and symptoms of IPF, which can accelerate referral to specialised care, reduce delays to accurate diagnosis and ensure timely access to treatment. Removing the access barriers to pharmacological treatment should also be a priority and could significantly improve the patient experience. This can be achieved by implementing more efficient treatment prescription rules and dispensing practices, and ensuring that available treatments are delivered to the right patient in a timely manner. Increasing access to multidisciplinary teams, including specialist nurses, is vital to challenge clinical inertia and improve patients’ quality of life.

The Report showed that major hurdles exist in access to non-pharmacological treatment options, including lung transplantation, supplemental oxygen, pulmonary rehabilitation, and palliative care. Long waiting lists and lack of donor organ availability represent some of the main hindrances to lung transplantation. Oxygen therapy and pulmonary rehabilitation can make a positive impact on patients’ quality of life but action must be taken to make it more available, accessible and affordable. Similarly, palliative care should be destigmatised and better embedded into IPF treatment plans. Finally, for patients living with IPF, access to psychological support is fundamental and must be offered systematically and holistically.

During the COVID-19 pandemic, rare disease patients - including patients living with IPF - have faced major obstacles and disruptions in access to care, including the cancellation of elective procedures and a high level of stress and uncertainty caused by lack of guidance from local and national authorities. It is therefore critical that all stakeholders come together to redesign healthcare services to ensure better preparedness and protection of people at-risk while maintaining the continuity of care in such circumstances. Further investigation is also needed to assess the full impact of COVID-19 on IPF management and care.
Across the countries surveyed, there is a clear need to accelerate diagnosis, improve access to treatment and standardise care pathways for patients living with IPF in order to address the important inequalities between and within countries.

Although healthcare delivery remains a Member State competence, there is a role for the EU to play in sharing best practices and pooling resources, to the benefit of all European patients living with IPF. The report also builds on some of the lessons learnt during the COVID-19 pandemic to provide key recommendations towards better healthcare systems preparedness and protection of people at-risk in times of public health crisis.

As public health has now become a priority for policy-makers at EU and national levels, there is a unique opportunity to foster radical policy change that can improve healthcare services and health outcomes. With the intent of supporting national policy-makers in preparing successfully for the next waves of the pandemic, EU-IPFF urges the adoption of specific protocols to provide guidance to IPF patients and ensure continuity of care. It is also utterly important that countries take action against triage protocols discriminating people because of age or any underlying health condition.

As there is a need to redesign and transform healthcare services to bring them closer to citizens and patients, EU-IPFF calls upon European policy-makers to:

- Ensure rare diseases remain a priority in the current European Commission Agenda.
- Encourage opportunities for rare disease patient groups to collaborate and build capacity through funding future programmes (including the European Social Fund Plus and the European Joint Programme on Rare Diseases).
- Ensure that the COVID-19 Clinical Management Support System is sustained in the long-term, to develop and disseminate guidelines and strategies to support at-risk populations, particularly the ones affected by rare lung diseases.
- Provide greater support to the integration and sustainability of established European Reference Networks for screening at-risk groups, expediting diagnosis and encouraging standardisation of rare disease care.

The EU-IPFF is committed to working with all stakeholders to ensure that action on rare diseases remains a priority area at the European and national level and support exchange of knowledge to guarantee that people with IPF have access to fair, equal and continuous quality care regardless of where they live in Europe.

**Call to action**

At a national level, there is an opportunity to improve the delivery of healthcare services, EU-IPFF calls upon national and regional governments to:

- Raise awareness of IPF amongst healthcare professionals to improve the recognition of early signs and symptoms.
- Ensure the implementation of IPF guidelines.
- Support collaboration and networking excellence at national and European levels (e.g. European Reference Networks), to better connect primary and secondary care and foster early diagnosis and timely access to treatment.
- Promote multi-disciplinary care and recognition of the role of specialised nurses at the national level.
- Recognise the burden and financial impact of IPF on patients and families, and ensure access to non-pharmacological treatment.
- Provide access to palliative care to all patients with IPF.
- Encourage the development of local support groups, given their role in providing patients with information and peer support.

At a national level, there is an opportunity to improve the delivery of healthcare services, EU-IPFF calls upon national and regional governments to:
## The European Scorecard

<table>
<thead>
<tr>
<th>INDICATORS</th>
<th>COUNTRIES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GUIDELINES</strong></td>
<td>AT</td>
</tr>
<tr>
<td>Availability of IPF guidelines (national and international)</td>
<td>BE</td>
</tr>
<tr>
<td>Implementation of IPF guidelines</td>
<td>BG</td>
</tr>
<tr>
<td>Assessment of IPF care pathways</td>
<td>DE</td>
</tr>
<tr>
<td>Guideline adherence</td>
<td>DK</td>
</tr>
<tr>
<td>Assessment of IPF care pathways</td>
<td>IE</td>
</tr>
<tr>
<td>Guideline adherence</td>
<td>EL</td>
</tr>
<tr>
<td>Assessment of IPF care pathways</td>
<td>ES</td>
</tr>
<tr>
<td>Guideline adherence</td>
<td>FI</td>
</tr>
<tr>
<td>Assessment of IPF care pathways</td>
<td>FR</td>
</tr>
<tr>
<td>Guideline adherence</td>
<td>HR</td>
</tr>
<tr>
<td>Assessment of IPF care pathways</td>
<td>HU</td>
</tr>
<tr>
<td>Guideline adherence</td>
<td>IT</td>
</tr>
<tr>
<td>Assessment of IPF care pathways</td>
<td>NL</td>
</tr>
<tr>
<td>Guideline adherence</td>
<td>PL</td>
</tr>
<tr>
<td>Assessment of IPF care pathways</td>
<td>RO</td>
</tr>
<tr>
<td>Guideline adherence</td>
<td>UK</td>
</tr>
</tbody>
</table>

**DIAGNOSIS AND ACCESS TO SPECIALISED CARE**

<table>
<thead>
<tr>
<th>INDICATORS</th>
<th>COUNTRIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment of diagnostic procedure</td>
<td>AT</td>
</tr>
<tr>
<td>Assessment of standardisation of IPF diagnosis</td>
<td>BE</td>
</tr>
<tr>
<td>Availability of information materials</td>
<td>BG</td>
</tr>
<tr>
<td>Assessment of self-management education tools</td>
<td>DE</td>
</tr>
<tr>
<td>Assessment of distribution and activities of specialised centres</td>
<td>DK</td>
</tr>
<tr>
<td>Availability of and access to multidisciplinary team</td>
<td>IE</td>
</tr>
<tr>
<td>Assessment of diagnostic procedure</td>
<td>EL</td>
</tr>
<tr>
<td>Assessment of standardisation of IPF diagnosis</td>
<td>ES</td>
</tr>
<tr>
<td>Availability of information materials</td>
<td>FI</td>
</tr>
<tr>
<td>Assessment of self-management education tools</td>
<td>FR</td>
</tr>
<tr>
<td>Assessment of distribution and activities of specialised centres</td>
<td>HR</td>
</tr>
<tr>
<td>Availability of and access to multidisciplinary team</td>
<td>HU</td>
</tr>
<tr>
<td>Assessment of diagnostic procedure</td>
<td>IT</td>
</tr>
<tr>
<td>Assessment of standardisation of IPF diagnosis</td>
<td>NL</td>
</tr>
<tr>
<td>Availability of information materials</td>
<td>PL</td>
</tr>
<tr>
<td>Assessment of self-management education tools</td>
<td>RO</td>
</tr>
<tr>
<td>Assessment of distribution and activities of specialised centres</td>
<td>UK</td>
</tr>
</tbody>
</table>

**ACCESS TO PHARMACOLOGICAL TREATMENT**

<table>
<thead>
<tr>
<th>INDICATORS</th>
<th>COUNTRIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Availability of pharmacological treatment</td>
<td>AT</td>
</tr>
<tr>
<td>Reimbursement of pharmacological treatment</td>
<td>BE</td>
</tr>
<tr>
<td>Assessment of distribution of prescription centres</td>
<td>BG</td>
</tr>
<tr>
<td>Availability of and access to multidisciplinary team</td>
<td>DE</td>
</tr>
<tr>
<td>Assessment of distribution of dispensation centres</td>
<td>DK</td>
</tr>
<tr>
<td>Availability of pharmacological treatment</td>
<td>IE</td>
</tr>
<tr>
<td>Reimbursement of pharmacological treatment</td>
<td>EL</td>
</tr>
<tr>
<td>Assessment of distribution of prescription centres</td>
<td>ES</td>
</tr>
<tr>
<td>Availability of and access to multidisciplinary team</td>
<td>FI</td>
</tr>
<tr>
<td>Assessment of distribution of dispensation centres</td>
<td>FR</td>
</tr>
<tr>
<td>Availability of pharmacological treatment</td>
<td>HR</td>
</tr>
<tr>
<td>Reimbursement of pharmacological treatment</td>
<td>HU</td>
</tr>
<tr>
<td>Assessment of distribution of prescription centres</td>
<td>IT</td>
</tr>
<tr>
<td>Availability of and access to multidisciplinary team</td>
<td>NL</td>
</tr>
<tr>
<td>Assessment of distribution of dispensation centres</td>
<td>PL</td>
</tr>
<tr>
<td>Availability of pharmacological treatment</td>
<td>RO</td>
</tr>
<tr>
<td>Reimbursement of pharmacological treatment</td>
<td>UK</td>
</tr>
</tbody>
</table>

**ACCESS TO NON PHARMACOLOGICAL TREATMENT**

<table>
<thead>
<tr>
<th>INDICATORS</th>
<th>COUNTRIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Availability of and access to oxygen therapy in the hospital</td>
<td>AT</td>
</tr>
<tr>
<td>Reimbursement of oxygen therapy in the hospital</td>
<td>BE</td>
</tr>
<tr>
<td>Availability of and access to oxygen therapy at home</td>
<td>BG</td>
</tr>
<tr>
<td>Reimbursement of oxygen therapy at home</td>
<td>DE</td>
</tr>
<tr>
<td>Availability of and access to pulmonary rehabilitation programmes</td>
<td>DK</td>
</tr>
<tr>
<td>Coverage of pulmonary rehabilitation programme</td>
<td>IE</td>
</tr>
<tr>
<td>Availability of and accessibility to information on clinical trials</td>
<td>EL</td>
</tr>
<tr>
<td>Availability of and access to pulmonary rehabilitation programmes</td>
<td>ES</td>
</tr>
<tr>
<td>Coverage of pulmonary rehabilitation programme</td>
<td>FI</td>
</tr>
<tr>
<td>Availability of and accessibility to information on clinical trials</td>
<td>FR</td>
</tr>
<tr>
<td>Availability of and access to pulmonary rehabilitation programmes</td>
<td>HR</td>
</tr>
<tr>
<td>Coverage of pulmonary rehabilitation programme</td>
<td>HU</td>
</tr>
<tr>
<td>Availability of and accessibility to information on clinical trials</td>
<td>IT</td>
</tr>
<tr>
<td>Availability of and access to pulmonary rehabilitation programmes</td>
<td>NL</td>
</tr>
<tr>
<td>Coverage of pulmonary rehabilitation programme</td>
<td>PL</td>
</tr>
<tr>
<td>Availability of and accessibility to information on clinical trials</td>
<td>RO</td>
</tr>
<tr>
<td>Availability of and access to pulmonary rehabilitation programmes</td>
<td>UK</td>
</tr>
</tbody>
</table>

**ACCESS TO PALLIATIVE CARE AND END-OF-LIFE CARE**

<table>
<thead>
<tr>
<th>INDICATORS</th>
<th>COUNTRIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Availability of and access to palliative care</td>
<td>AT</td>
</tr>
<tr>
<td>Coverage of palliative care</td>
<td>BE</td>
</tr>
<tr>
<td>Availability of palliative care centres and mobile teams</td>
<td>BG</td>
</tr>
<tr>
<td>Inclusivity of decision-making process for patients and families in palliative care</td>
<td>DE</td>
</tr>
<tr>
<td>Availability of and access to palliative care</td>
<td>DK</td>
</tr>
<tr>
<td>Coverage of palliative care</td>
<td>IE</td>
</tr>
<tr>
<td>Availability of palliative care centres and mobile teams</td>
<td>EL</td>
</tr>
<tr>
<td>Inclusivity of decision-making process for patients and families in palliative care</td>
<td>ES</td>
</tr>
<tr>
<td>Availability of and access to palliative care</td>
<td>FI</td>
</tr>
<tr>
<td>Coverage of palliative care</td>
<td>FR</td>
</tr>
<tr>
<td>Availability of palliative care centres and mobile teams</td>
<td>HR</td>
</tr>
<tr>
<td>Inclusivity of decision-making process for patients and families in palliative care</td>
<td>HU</td>
</tr>
<tr>
<td>Availability of and access to palliative care</td>
<td>IT</td>
</tr>
<tr>
<td>Coverage of palliative care</td>
<td>NL</td>
</tr>
<tr>
<td>Availability of palliative care centres and mobile teams</td>
<td>PL</td>
</tr>
<tr>
<td>Inclusivity of decision-making process for patients and families in palliative care</td>
<td>RO</td>
</tr>
<tr>
<td>Availability of and access to palliative care</td>
<td>UK</td>
</tr>
</tbody>
</table>

**Inclusivity of decision-making process for patients and families in palliative care**

<table>
<thead>
<tr>
<th>INDICATORS</th>
<th>COUNTRIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Availability of and access to palliative care</td>
<td>AT</td>
</tr>
<tr>
<td>Coverage of palliative care</td>
<td>BE</td>
</tr>
<tr>
<td>Availability of palliative care centres and mobile teams</td>
<td>BG</td>
</tr>
<tr>
<td>Inclusivity of decision-making process for patients and families in palliative care</td>
<td>DE</td>
</tr>
<tr>
<td>Availability of and access to palliative care</td>
<td>DK</td>
</tr>
<tr>
<td>Coverage of palliative care</td>
<td>IE</td>
</tr>
<tr>
<td>Availability of palliative care centres and mobile teams</td>
<td>EL</td>
</tr>
<tr>
<td>Inclusivity of decision-making process for patients and families in palliative care</td>
<td>ES</td>
</tr>
<tr>
<td>Availability of and access to palliative care</td>
<td>FI</td>
</tr>
<tr>
<td>Coverage of palliative care</td>
<td>FR</td>
</tr>
<tr>
<td>Availability of palliative care centres and mobile teams</td>
<td>HR</td>
</tr>
<tr>
<td>Inclusivity of decision-making process for patients and families in palliative care</td>
<td>HU</td>
</tr>
<tr>
<td>Availability of and access to palliative care</td>
<td>IT</td>
</tr>
<tr>
<td>Coverage of palliative care</td>
<td>NL</td>
</tr>
<tr>
<td>Availability of palliative care centres and mobile teams</td>
<td>PL</td>
</tr>
<tr>
<td>Inclusivity of decision-making process for patients and families in palliative care</td>
<td>RO</td>
</tr>
<tr>
<td>Availability of and access to palliative care</td>
<td>UK</td>
</tr>
</tbody>
</table>

**Availability of and access to home hospice**

<table>
<thead>
<tr>
<th>INDICATORS</th>
<th>COUNTRIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Availability of and access to palliative care</td>
<td>AT</td>
</tr>
<tr>
<td>Coverage of palliative care</td>
<td>BE</td>
</tr>
<tr>
<td>Availability of palliative care centres and mobile teams</td>
<td>BG</td>
</tr>
<tr>
<td>Inclusivity of decision-making process for patients and families in palliative care</td>
<td>DE</td>
</tr>
<tr>
<td>Availability of and access to palliative care</td>
<td>DK</td>
</tr>
<tr>
<td>Coverage of palliative care</td>
<td>IE</td>
</tr>
<tr>
<td>Availability of palliative care centres and mobile teams</td>
<td>EL</td>
</tr>
<tr>
<td>Inclusivity of decision-making process for patients and families in palliative care</td>
<td>ES</td>
</tr>
<tr>
<td>Availability of and access to palliative care</td>
<td>FI</td>
</tr>
<tr>
<td>Coverage of palliative care</td>
<td>FR</td>
</tr>
<tr>
<td>Availability of palliative care centres and mobile teams</td>
<td>HR</td>
</tr>
<tr>
<td>Inclusivity of decision-making process for patients and families in palliative care</td>
<td>HU</td>
</tr>
<tr>
<td>Availability of and access to palliative care</td>
<td>IT</td>
</tr>
<tr>
<td>Coverage of palliative care</td>
<td>NL</td>
</tr>
<tr>
<td>Availability of palliative care centres and mobile teams</td>
<td>PL</td>
</tr>
<tr>
<td>Inclusivity of decision-making process for patients and families in palliative care</td>
<td>RO</td>
</tr>
<tr>
<td>Availability of and access to palliative care</td>
<td>UK</td>
</tr>
</tbody>
</table>
General introduction and guidelines

According to a national survey conducted in Austria, national guidelines are currently in preparation. In the meantime, Austria implements ATS/ERS/JRS/ALAT international IPF guidelines.

In 2011, the Austrian Health Ministry created a national coordination centre for rare diseases (Nationale Koordinationsstelle für seltene Erkrankungen - NKSE). The objective of this centre is to improve care for people living with rare diseases. Its current priority is the coordination of Austrian hospitals participating in European Reference Networks, and the establishment of reference centres and care pathways for rare diseases.

In addition, in 2014, the Austrian government issued an action plan for rare diseases called NAP.se. A condensed five-page document can be found here. The action plan has nine concrete actions which aim to be worked on until 2018. An update is expected in 2019.

Diagnosis and access to specialised care

Key challenge: Although diagnosis is considered standardised in clinics caring for IPF patients, timely referral and late diagnosis remain a challenge.

There are no official ILDs specialised centres in Austria but some centres have expertise in ILDs and work with multidisciplinary teams. In 2015, the Ministry of Health said they would prioritise the establishment of centres that are specialised in rare diseases. A list of six disease areas was prioritised; lung fibrosis was not part of this list. The specialised rare diseases centres to be established in 2018/2019 include: dermatology, facial deformities, bone diseases, paediatric diseases, growth impairment, epileptic diseases and movement disabilities.

In clinics caring for IPF patients, the diagnostic procedure has been reported to be standardised. International IPF guidelines are properly implemented and multidisciplinary discussions take place to support diagnosis. Upon diagnosis, information materials are available for patients, most of the time through local patient support groups.

Key challenge: The ‘wait and watch’ approach has been flagged as one of the main barriers to prompt access to pharmacological treatment.

EMA-approved pharmacological treatments for IPF are available and reimbursed with no out-of-pocket costs for patients.

The pharmacological treatments can be prescribed by the clinics following IPF patients and/or by a respiratory physician; they are dispensed by community pharmacies. Nevertheless, the lack of disease awareness results in treatment access delays.

Access to non-pharmacological treatment

Key challenge: IPF patients do not have access to specialised ILD nurses and there are no pulmonary rehabilitation programmes specifically designed to IPF patients.

Non-pharmacological treatment options are available to IPF patients in Austria and the costs associated with these treatments are reimbursed. Oxygen therapy at home or in hospital is available to patients upon prescription by the treating clinics or the respiratory physician. Pulmonary rehabilitation programmes are also available in hospital, but they do not necessarily take into account the specific needs of IPF patients. Lung transplantation is an option, however the patient’s age, general health condition and the risks associated with transplantation could represent serious barriers. IPF patients have access to clinical trials.

Access to palliative care and end-of-life care

Key challenge: The important role that palliative care can play in ensuring a better quality of life for IPF patients is not fully recognised.

Palliative care is available to IPF patients in Austria and it is normally delivered in clinics with palliative care units; mobile palliative care teams are also an option. However, long waiting times for hospice care have been reported.

In the overall patient journey, the respiratory physician, the multidisciplinary team and the patient groups are the ones providing relevant support to IPF patients and their families. Additional psychological and emotional support for patients and their carers would be needed.

Patient statement

“In Austria there are gaps in the availability of non-pharmacological care. In particular, there is no satisfactory IPF home care service and IPF patients do not have access to a specialised ILD nurse. In some rehabilitation centres too little attention is paid to the specific needs of IPF patients. Unfortunately, there are hardly any educational tools for patients on IPF self-management. Local patient support groups and healthcare professionals tackle these issues and provide support to patients and their families.”

Günther Wanke, Lungenfibrose Forum-Austria
**General introduction and guidelines**
The ATS/ERS/JRS/ALAT international IPF guidelines are implemented in specialised centres in Belgium but there are no national IPF guidelines. In Belgium there is also a rare disease plan which was published in 2013.

**Diagnosis and access to specialised care**
Seven centers in Belgium have the general rare disease entry, but this is not on the level of the different diseases.

Diagnostic procedures for IPF are standardised within ILD centres, where IPF care pathways are in place and follow-up is performed. The ILD centres work with different satellite centres in a hub and spoke model but there is no structured cooperation with primary care.

IPF guidelines are properly implemented in the ILD centres and multidisciplinary discussions take place. Upon diagnosis, informative materials are available to patients, usually thanks to local patient support groups.

**Key challenge:** Delayed diagnosis and timely referral remain major challenges in Belgium. Recognising early signs and symptoms of IPF is considered to be essential to accelerate patient referral to a respiratory specialist.

**Access to non-pharmacological treatment**
EMA-approved pharmacological treatments for IPF are available and reimbursed with no out-of-pocket costs for Belgian patients. The pharmacological treatments are prescribed and dispensed by the ILD centres (at this moment only 3 centres comply with the criteria to prescribe).

**Key challenge:** Non-pharmacological treatment options are available for IPF patients in Belgium and costs are reimbursed. Oxygen therapy at home or in hospital are available to patients upon doctor prescription. Pulmonary rehabilitation programmes are also available in hospital but only 60% of the costs are reimbursed by the health insurance (additional costs might be covered by a complementary health insurance).

Although lung transplantation can be offered to IPF patients, there are big differences in how ILD centres assess and weigh criteria to offer lung transplantation. IPF patients have access to clinical trials.

**Access to palliative care and end-of-life care**
Palliative care is available to IPF patients in Belgium. It is normally delivered in hospital, at home or in specialised centres. As highlighted in a 2017 report for the European Institute of Bioethics, Belgium is ranked quite high for its performance in and availability of palliative care. The main palliative care hurdles are that it is often proposed too little and too late, it should be more embedded in traditional care and home availability of palliative care should be reinforced.

In the overall patient journey, the respiratory physician, the specialist nurse together with other members of the multidisciplinary team (such as the psychologist and the assistant nurse) are the ones providing relevant support to the IPF patients and their families. Patient groups also play an important role when it comes to psychological and emotional support for patients and their carers.

**HCP statement**
“It is vital that primary care physicians listen for the initial signs and symptoms of IPF (especially the Velcro-like crackles) and refer patients to a respiratory specialist. Through a network of specialised doctors, even the more complex patients could be quickly referred to the ILD centres.”

**Prof. Wim Wuyts, University Hospital Leuven**
The ATS/ERS/JRS/ALAT international IPF guidelines are available in Bulgaria; however, they are not always correctly implemented in the Bulgarian centres. No national IPF guidelines are available. IPF is included in the list of rare diseases. However, the disease file including information about the course of disease and its prognosis is still under development.

**Key challenge:** Delayed diagnosis and lack of communication between the general practitioner and the respiratory physician have been reported as the main challenges in Bulgaria. Timely referral to a respiratory specialist would ensure accurate diagnosis and faster access to treatment.

In Bulgaria there are no specialised ILD centres but there are 6 hospitals specialised in lung diseases, which do not operate fully as specialised centres (the University Hospital of respiratory diseases “St. Sofia” - Sofia Medical University; the pulmonary department of the Military Hospital Sofia - Medical Faculty of Sofia University; the Acibadem City Clinic Tokuda Hospital in Sofia; the University Hospital "St. George" - Plovdiv Medical University; the University Hospital "St. Marina" - Medical University Varna; the University Hospital "G. Stranski" - Medical University Pleven).

IPF guidelines are only partially implemented in these hospitals. Although multidisciplinary teams (MDTs) are becoming more common in Bulgarian hospitals, MDTs for IPF care are available and fully in place in only one centre. There are no ILD nurses who can support patients in their daily lives. Upon diagnosis, information materials are available to patients, mainly provided by the local patient support groups.

**EMA-approved pharmacological treatments for IPF are available and reimbursed with no out-of-pocket costs for Bulgarian patients. The pharmacological treatments can be prescribed by five of the clinics specialised in lung diseases and they are dispensed by community pharmacies.**

The current prescription rules might represent a barrier to access to pharmacological treatment; it has been reported that allowing general practitioners or respiratory physicians to prescribe treatment has the potential to improve the issue.

### Key challenge: Access to non-pharmacological treatment

Non-pharmacological treatment options are available to IPF patients in Bulgaria but the costs associated with these treatments are not always fully reimbursed. Oxygen therapy is available in hospital and at home but is only reimbursed in the case of the former. Pulmonary rehabilitation programmes for patients with chronic lung diseases are available in hospital but no specific IPF programmes have been developed. The costs are covered only for a period of 10 days per year and any additional days are at the expense of the patient. Lung transplantations are not performed in Bulgaria. IPF patients in Bulgaria have access to clinical trials.

### Key challenge: Access to palliative care and end-of-life care

Palliative care is available to IPF patients in Bulgaria but it is not reimbursed by the national healthcare system. Only private hospices provide this type of care and the costs can be high. In the overall patient journey, the families and local support groups are the ones providing relevant support to IPF patients.

### Patient representative statement

"Delayed diagnosis is a big issue in Bulgaria and it is mainly due to lack of knowledge of the disease at primary care level and late referrals to respiratory physicians. In addition, the lack of communication between specialised centres and the National Health Insurance Fund, which reimburses the treatment, causes further delays in access to pharmacological treatments. We at IPF Bulgaria, hope that this situation will improve soon so that access to pharmacological treatments for IPF patients will not be delayed unnecessarily."

**Todor Mangarov, IPF Bulgaria**
No national IPF guidelines are available in Croatia and the international guidelines are not consistently implemented across the country.

IPF care pathways do exist in Croatia. However, patients are not always referred timely to the ILD centres as primary care providers do not seem to be familiar enough with recognising the signs and symptoms of ILDs and IPF in particular.

No official list of rare diseases is available in Croatia, but a national rare diseases plan exists, which is available at this link in Croatian. However, this plan does not seem to be fully and correctly implemented.

IPF is considered a rare disease in Croatia. While there were steps taken towards the creation of a national registry of rare lung diseases, such a registry still does not exist.

Patient engagement in policy development remains very minimal and only some occasional meetings with government representatives take place.

**Key challenge:** Misdiagnosis, late diagnosis and late referral to an ILD centre still represent barriers to access to specialised care for IPF patients in Croatia.

Policies to support early diagnosis are in the process of being set up. In 2020, the government is starting a national programme for lung cancer screening, which will also include screening for ILDs. According to this programme, general practitioners will have to refer patients with suspected IPF to an ILD centre for a CT scan. However, not all ILD centres are equipped with the necessary diagnostics tools.

The overall diagnostic process is still not standardised across the country. There are four ILD centres that provide treatment and follow-up care to ILD patients. Follow-up care can also take place in some general hospitals.

Additionally, multidisciplinary teams are available in all four centres, including the Department of Respiratory Diseases in the UHC Zagreb.

Upon diagnosis, IPF patients can refer to the local patient support group to have access to relevant materials as IPF information tools are not provided directly by the National Health System.

**Key challenge:** Patients are sometimes treated with a pharmacological treatment which is not appropriate as a result of a misdiagnosis.

The two EMA-approved pharmacological treatments for IPF are available and fully reimbursed by the Croatian social security system. However, there are some differences in the prescription rules, depending on disease severity.

The respiratory physician can prescribe the pharmacological treatment after discussing with the multidisciplinary team and the prescription needs to be renewed once a month. The treatment is dispensed only at the ILD centre.

**Key challenge:** IPF patients do not have access to ambulatory oxygen in Croatia.

IPF patients do not have access to ambulatory oxygen in Croatia. However, oxygen therapy at home is available for IPF patients and it is fully reimbursed.

Pulmonary rehabilitation programmes are available in hospitals or ambulatory and they are fully covered by the social security system.

Lung transplants are performed in Croatia. In 2019, 7 patients received a lung transplant but none of them were IPF patients. The patients were chosen using the international guidelines for the selection of lung transplant candidates. The most common contraindications for lung transplantation include: age, risk associated with transplantation due to comorbidities and current smoking status.

**Key challenge:** IPF patients do not have access to home hospice in Croatia.

IPF patients have access to palliative care and it is partially reimbursed by the social security system. However, there are geographical inequalities in access to palliative care.

Palliative care centres are available and IPF patients and their families are involved in decisions regarding palliative care. However, no information materials on palliative care are available.

Some centres participate in clinical trials and patients do receive some information about open clinical trials from their physicians.

In the overall care journey, the respiratory physician, the specialist nurses and the patient advocacy groups are providing relevant support to IPF patients and their relatives. However, no support is offered specifically to carers.

**Patient representative statement**

"It is critical to recognise early symptoms of the disease, in collaboration with a multidisciplinary team, to design an individual treatment plan, which may slow the decline in lung function, increase quality of life and improve prognosis."

*Sandra Karabatić, President of “Jedra”*
National IPF guidelines were developed by the Danish Society of Respiratory Medicine in 2011 and were updated in 2016; another update is forecasted for 2020 as the Society aims to review the guidelines every 2 years. The guidelines are the reference document for healthcare professionals and seem to be correctly implemented across Denmark. In addition, at the local level the three Danish ILD centres have developed extensive guidelines on diagnosis and treatment.

IPF is recognised as a rare disease in Denmark and the Danish National ILD Database (DANILDA) was put in place by the three ILD centres. While there are no rare diseases plan, the national health authorities have developed specialty plans, including a specific plan for pulmonary diseases.

Diagnosis of IPF seems to be currently standardised across Denmark, as the national IPF guidelines - which cover diagnosis and treatment – are implemented across the country. In Denmark, there are three University Hospitals which act as specialised centres for ILD. They are well distributed across the country, thus enabling good geographical coverage of IPF patients. Follow-up visits also take place in the same hospitals, allowing for long term care.

Upon diagnosis, IPF patients have access to information directly from nurses and a handbook, developed by the ILD centres. The Lung Associations Patient Group has also developed a report.

In addition, multidisciplinary teams (e.g. including radiologists and pathologists) are in place and hold internal meetings on a weekly basis. Although nurses are involved in relevant discussions around diagnosis and management, the participation of other healthcare professionals (including physiotherapists, dieticians, psychologists) needs to be reinforced. Of note, patients do not attend multidisciplinary team meetings.

The two EMA-approved pharmacological treatments for IPF are available and fully reimbursed by the social security system. Timely access to treatment could be improved if the disease is diagnosed earlier, hence the need to raise awareness of IPF among general practitioners.

The treatments are prescribed by the specialised centres and dispensed by hospital pharmacies or can be sent directly to the patient’s home. When treatment is initiated, patients only receive prescriptions for one month but they can receive prescriptions for up to 3 months at a later stage.

Non-pharmacological treatment options are available to IPF patients and the costs associated with these treatments are fully reimbursed, whether it is ambulatory oxygen or long-term oxygen treatment (LTOT). Reimbursement also covers the operating costs linked to oxygen support.

The most common system through which oxygen is administered is via the oxygen concentrator at home, but portable oxygen concentrators are also available. On a case-by-case basis, patients may also be prescribed oxygen therapy at home.

As rehabilitation programmes are managed at the local level, not all IPF patients have access to them. In some regions, they only cover chronic obstructive pulmonary disease (COPD) while in some others, IPF patients may have access to general lung rehabilitation programmes. The latter are usually performed at local community centres for a period of 8 weeks and the cost is fully reimbursed.

Lung transplants are managed by Scandiatransplant, the organ exchange organisation for Denmark, Finland, Iceland, Norway, Sweden and Estonia. The international guidelines for the Selection of Lung Transplant Candidates are used.

Finally, there are 3 centres in Denmark participating in clinical trials on IPF.

IPF patients have limited access to palliative care as in practice it is mainly delivered to oncology patients. In addition, the referral process varies between regions. In some of them, general practitioners can take the decision to refer to specialised palliative care centres while in others, pulmonologists will be in charge of the referral. Patients and their families are always involved in decisions regarding palliative care.

Patients can benefit from home hospices and mobile palliative care teams can offer support to patients for end-of-life care. Also, nursing homes (hospices) are available for end-of-life care. However, there is the need for more rehabilitation centres and more mobile palliative care teams. In the Copenhagen area, new services dedicated to pulmonary patients are being established (e.g. cancer, COPD, IPF).

In the overall care journey, the respiratory physician, specialist nurses and families are the ones providing relevant support to IPF patients and their relatives. Reimbursement is offered to carers of terminally ill patients.

"IPF diagnosis and care has a high priority in Denmark due to national specialty planning that ensures rapid referral to dedicated ILD centres when IPF is suspected. Antifibrotic and non-pharmacological treatment is fully reimbursed."

Elisabeth Bendstrup, MD, Ph.d., Department of Respiratory Diseases and Allergology, Aarhus University Hospital
The ATISERS/JRS/ALAT international IPF guidelines are implemented in Finland. Additionally, the national IPF guidelines are presented in the Finnish Textbook of Respiratory Medicine, which is available in every hospital and health care center. The textbook is currently being updated. These guidelines are also provided to healthcare professionals for education purposes by the Finnish Respiratory Society. Moreover, some hospitals have developed their own guidelines for IPF diagnosis and care, such as the Turku and Oulu University Hospitals.

Although there is no national list of rare diseases in Finland, IPF is recognised as a rare disease. Since 2012, Finland has been collecting data on the incidence of and clinical data on patients with IPF in order to support research, from diagnosis to treatment. The registry spans all pulmonary medicine units across Finland.

In 2019, the Social and Health Ministry published the updated Rare Diseases Plan for the period 2019-2023, that presents the national strategy on rare diseases for Finland. However, IPF is not explicitly mentioned in the rare diseases plan.

Key challenge: There are no pulmonary rehabilitation services which are specifically dedicated to patients with IPF. Additionally, pulmonary rehabilitation is not available in all University Hospitals.

Non-pharmacological treatment options are available to IPF patients. Oxygen therapy is available both in hospitals and at home. Medical oxygen prescribed by a doctor is partially reimbursed (Social insurance Institution of Finland, Kela). Patients can also receive oxygen concentrators free of charge from the hospital without a prescription.

The Social Insurance Institution of Finland (Kela), offers rehabilitation programmes for patients with rare lung diseases; however, there are no pulmonary rehabilitation services which are exclusively tailored to patients with IPF. Patients are normally referred to a physiotherapist at a health centre where pulmonary rehabilitation programmes are available and free of charge but they are sometimes limited in time. Additionally, Finland has developed a national education programme focused on outpatient rehabilitation.

Lung transplants are managed by Scandiatransplant, the organ exchange organisation for Denmark, Finland, Iceland, Norway, Sweden and Estonia. The international guidelines for the Selection of Lung Transplant Candidates are used.

Finally, IPF patients have access to clinical trials both at the University Hospitals of Oulu and Helsinki.

Key challenge: Some University Hospitals have limited access to palliative care, leading to geographical differences across the country.

Palliative care is available in Finland and fully reimbursed upon doctor prescription. Patients can have access either to palliative care units in hospitals or health centres, or they can be supported by mobile palliative teams at home. In addition, nurses can provide home hospice. Moreover, the palliative care plan always involves the patients and their families. However, there is the need to ensure that additional training is made available for palliative care teams.

In the overall patient care journey, the respiratory physician, the specialist nurses and the patient support groups are the ones providing relevant support to IPF patients and their relatives.

Carers, when officially recognised by the municipality, are also offered financial compensation and are entitled to some days off from work.

Patient representative statement

"Awareness of IPF has increased in Finland in the course of the last years. However, access to treatment and non-pharmacological care for IPF patients are not standardised across the country, leading to inequalities among patients. More work needs to be done to ensure that IPF patients receive proper palliative care and that outpatient pulmonary rehabilitation is widely available to them."

Marika Kiiikalaisuuo, Hengitysliitto
### General introduction and guidelines

The ATS/ERS/JRS/ALAT international IPF guidelines are implemented in specialised centres in France. In 2017, the network of rare diseases in France published national guidelines on the diagnosis and treatment of IPF (available [here](#)). OrphaLung, the network of rare pulmonary diseases centres, is accredited by the French Ministry of Health and treats numerous rare pulmonary conditions, including IPF.

### Diagnosis and access to specialised care

**Key challenge:** Timely referral has been reported as the main challenge in France. Recognising early signs and symptoms of IPF is considered to be essential to accelerate patient referral to a respiratory specialist.

There are 23 specialised centres for rare pulmonary diseases in adults in France. They are integrated in the OrphaLung network (Network of rare pulmonary diseases centres). OrphaLung is part of RespiFil which, in addition to the centres involved in OrphaLung, brings together reference centres and competence centres working on paediatric rare pulmonary diseases and pulmonary hypertension.

This is very helpful for physicians to refer difficult cases of ILD; however not all patients need to be referred to these centres as some centres work well with primary care providers.

The diagnosis process is pretty much standardised, as the French IPF guidelines are properly implemented and multidisciplinary teams are available in the specialised centres. However, there is some heterogeneity in clinical practice and quality of care, as well as a certain lack of education and information, which if solved could lead to earlier diagnosis.

### Access to pharmacological treatment

**Key challenge:** Ensuring timely diagnosis can contribute to guaranteeing timely access to pharmacological treatment.

EMA-approved pharmacological treatments for IPF are available and reimbursed with no out-of-pocket costs to patients.

The pharmacological treatments can be prescribed by specialised centres and hospital respiratory physicians and are dispensed by community pharmacies (upon order placement).

### Access to non-pharmacological treatment

Non-pharmacological treatment options are available to IPF patients in France and costs are reimbursed.

Oxygen therapy at home or in hospital are available to patients upon doctor prescription.

Pulmonary rehabilitation programmes are also available in hospital and at home; however rehabilitation needs to be initiated in the hospital. Some issues remain such as the geographical distribution and availability of outpatient rehabilitation centres across France as this is not well organised and not available everywhere. Reimbursement of pulmonary rehabilitation is available, if it has been initiated in long-term and rehabilitation care units.

Lung transplantation is an option for patients. However the age, the overall health status and the progression of the disease could represent serious barriers.

IPF patients in France have access to clinical trials through the OrphaLung network.

### Access to palliative care and end-of-life care

**Key challenge:** Although palliative care is available, patients have expressed the need for more support around palliative care and pain management.

Palliative care is available to IPF patients and it is normally delivered in hospitals or in specialised palliative care centres. However, palliative care is mainly dedicated to oncology patients, hence there is limited access for patients with IPF.

However not all patients have access to it in a timely manner. A recent survey conducted with IPF and PF patients showed that 18% of surveyed patients expressed the need for more support around palliative care and pain management.

In the overall patient journey, the respiratory physician and the specialist nurse are the ones providing relevant support to the IPF patients and their families. Patient groups also play an important role when it comes to providing psychological and emotional support to patients and their carers.

### HCP statement

“Many patients and primary care providers are not aware of the OrphaLung network of ILD centres. We hear stories of patients being referred to the cardiologist first, then to a pulmonologist before finally coming to the expert centre. It feels like a relief for patients to finally have an accurate diagnosis, with detailed information given to them with regards to what to expect from treatment and prognosis.”

Vincent Cottin, CHU Lyon
Germany has national IPF guidelines and recognizes international guidelines (ATS/ERS/JRS/ALAT). The German national guidelines were published in the medical journal Pneumologie in 2003 and were updated in 2017 to include new treatment therapies. The guidelines were also translated and updated into English in 2018. The national guidelines were developed under the umbrella initiative, Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin – The German Association for Pneumology and Airway-medicine.

IPF is included in the national list of rare diseases. In addition, since 2012 Germany has been collecting and analysing data on the burden of IPF across the country through an expert-driven IPF registry called INSIGHTS-IPF (results are available here - log-in information required). An ILD registry from in and out-patient facilities - the EXCITING registry – is also available.

Key challenge: The lack of general IPF awareness is leading to delayed specialist referrals and consequently delays timely access to treatment.

The national guidelines on IPF, including recommendations on diagnosis, have been updated in 2017 and are available at this link. This document mainly discusses the various treatment options. Section 3 (pp. 85-90) of the original German guidelines, published in 2013, provided an illustration of the diagnostic pathway (figure 3); it is now commonly used across Germany. Despite various resources, the referral to specialist care remains a key challenge and consequently delays access to treatment.

There are 25 specialised ILD centres across Germany, where multidisciplinary teams are in place. Upon diagnosis, informative materials are available for patients, mainly provided by the local patient support groups.

Key challenge: Early diagnosis and timely access to treatment remain the main challenges. Ensuring patients go to the general practitioner can be the first step towards early diagnosis.

EMA approved pharmacological treatments for IPF are available and reimbursed with no out-of-pocket costs for patients in Germany. The pharmacological treatments can be prescribed by the specialised centres, by the respiratory physician and by other physicians with experience in the diagnosis and treatment of IPF. The treatments are dispensed by community pharmacies.

Key challenge: Early diagnosis and timely access to treatment remain the main challenges. Ensuring patients go to the general practitioner can be the first step towards early diagnosis.

Non-pharmacological treatment options are available to IPF patients and costs are reimbursed. According to the German IPF guidelines, various non-pharmacological treatment options are recommended including long-term oxygen therapy, lung transplantation and pulmonary rehabilitation. These therapy options are available in hospital and in some cases at home upon doctor’s prescription. All therapy options are reimbursed if a doctor’s prescription is available. Patients have mentioned that challenges persist if the patient requires pulmonary rehabilitation at home. Pulmonologists and specialised centres are also aware of ongoing clinical trials and they communicate this to patients when applicable.

Non-pharmacological treatment options are available to IPF patients and costs are reimbursed. According to the German IPF guidelines, various non-pharmacological treatment options are recommended including long-term oxygen therapy, lung transplantation and pulmonary rehabilitation. These therapy options are available in hospital and in some cases at home upon doctor’s prescription. All therapy options are reimbursed if a doctor’s prescription is available. Patients have mentioned that challenges persist if the patient requires pulmonary rehabilitation at home. Pulmonologists and specialised centres are also aware of ongoing clinical trials and they communicate this to patients when applicable.

Palliative care is available to IPF patients and is normally reimbursed upon doctor’s prescription. End-of-life care is provided by hospices, palliative care facilities and family carers at home.

In the overall patient journey, the family, the respiratory physician and the patient support group are the ones providing relevant support to the IPF patients and their families. Patient groups also play an important role when it comes to providing psychological and emotional support for patients and their carers. Nevertheless, the lack of information and communication about options beyond pharmacological treatments may be a barrier for patients in Germany. Communication to patients and their families about palliative care in general and end-of-life care in particular is still influenced and made difficult by the general misconception of palliative care as medicines for dying patients.

Patient statement

“As a patient I feel like my doctor should explain to me the benefits of palliative care already at the early stage of the disease so that I would have more time to better understand how it can help me in my daily life, before it really becomes necessary.

I also do not have a clear idea about how the end-of-life stage will look like and I feel there should be more communication about this because it is not only physically but also psychologically very challenging to deal with this disease.”

Klaus Geissler, Lungenfibrose e.V
General introduction and guidelines

The ATS/ERS/JRS/ALAT 2018 international IPF guidelines are not always correctly implemented in Greece. The Hellenic Thoracic Society and the Scientific Society for Rare Diseases & Orphan Drugs organise a number of scientific activities for physicians throughout the year that help address some of the implementation issues.

The Greek Alliance of Rare Diseases refers to the ORPHANET’s list of rare diseases among which IPF is included. However, an official list is not available.

Diagnosis and access to specialised care

Key challenge: Getting a correct and timely diagnosis is very challenging as general practitioners are not always aware of the disease.

There are a few specialised centres in major Greek cities; however, there are no IPF patient pathways in place. Misdiagnosis and late diagnosis are very common in the country as multidisciplinary teams are not available to patients.

Upon diagnosis, information materials are available for patients; they are provided by the existing patient support group and the specialised centres.

Access to pharmacological treatment

EMA-approved pharmacological treatments for IPF are available and reimbursed with no out-of-pocket costs for patients. The pharmacological treatments can only be prescribed by physicians working in state or private hospitals. These physicians need to submit an application - including all the necessary examinations – to a government-approved committee and it might take up to 10-15 days in order to get an approval (due to the treatment’s high cost). This can result in long waiting times for patients. There are also issues with point-of-care dispensing as the pharmacological treatment can only be dispensed by the national health scheme pharmacies.

Access to pharmacological treatments also differs from one city to another. In fact, in smaller cities, the distribution system is more efficient and less exhausting for the patient, who receives the pharmacological treatment at home by post. On the contrary, in larger cities patients experience long waiting times in order to get the treatment.

Access to non-pharmacological treatment

Non-pharmacological treatment options are not always available and fully reimbursed for IPF patients in Greece. For example, to have access to liquid oxygen, patients need to pay 25% of the cost.

IPF patients do not have easy access to pulmonary rehabilitation programmes, since only a few hospitals provide this service. At the moment, there is no lung transplantation centre in Greece. Greek patients have to go to a lung transplantation centre abroad (usually in Austria). Given that there are not enough lung donors from Greece the majority of Greek candidates cannot receive a transplant, even abroad.

There are a few Greek centres participating in clinical trials but access to these trials seems to be problematic for patients.

Access to palliative care and end-of-life care

Palliative care is offered only in a few hospitals in the country. Home hospice is not a viable option for patients.

Families and respiratory physicians are the ones providing relevant support to IPF patients. IPF has a huge impact on family members acting as the patient carer; there is a significant loss in terms of productivity at work for these relatives who would need to quit their job to take care of the patients.

Patient statement

“In addition to proper and effective medical and professional help, patients need the support of family, friends and patient organisations at both national and European level, to give us hope, and belief in a better future for IPF patients.”

Anthony Antoniou, Hellenic Pulmonary Fibrosis Association
General introduction and guidelines

The ATS/ERS/JRS/ALAT international IPF guidelines are implemented throughout the country. Hungarian adaptation of the international guidelines is under development.

Diagnosis and access to specialised care

**Key challenge:** The lack of standardised diagnostic process and delayed diagnosis remain the main challenges in Hungary.

There are 12 specialised ILD centres in Hungary. The diagnostic process is not standardised and varies depending on each centre’s experience. Upon diagnosis, information materials are available for patients at the specialised centres and are provided by local patient support groups.

Access to pharmacological treatment

**Key challenge:** Long waiting times to be referred to a specialised centre might hinder prompt access to pharmacological treatment for patients.

EMA-approved pharmacological treatments for IPF are available and reimbursed to patients. The pharmacological treatments can only be prescribed by ILD centres but can be dispensed by any community pharmacy.

Access to non-pharmacological treatment

Non-pharmacological treatment options are not always available and fully reimbursed to IPF patients in Hungary. Supplemental oxygen for travelling is only available in liquid form and this reduces patients’ longterm mobility.

**Key challenge:** Long waiting times to be referred to a specialised centre might hinder prompt access to pharmacological treatment for patients.

EMA-approved pharmacological treatments for IPF are available and reimbursed to patients. The pharmacological treatments can only be prescribed by ILD centres but can be dispensed by any community pharmacy.

Access to palliative care and end-of-life care

**Key challenge:** Patients have limited access to palliative care.

Palliative care can be provided at home and at certain inpatient care facilities. It is considered a last resort option when other therapeutic options have been exhausted.

In the overall patient journey, the respiratory physician and specialist nurse are the ones providing relevant support to IPF patients.

Patient statement

“Unfortunately IPF is still an unknown rare disease. A significant effort is needed to raise awareness of IPF, especially among primary care providers, to make sure that patients are referred to the specialised centres. There is a lot to be done to increase IPF patients access to ambulatory oxygen and palliative care, and to ensure they receive adequate support for reduced mobility from the government.”

**Maria Rigo, Magyar Tudofibrozis Egyesulet**
The ATS/ERS/JRS/ALAT international IPF guidelines seem to be correctly implemented in Ireland. In August 2018, national guidelines were developed by the Irish Thoracic Society (ITS) and a Position Statement on the Management of Idiopathic Pulmonary Fibrosis (available here) was published. These guidelines are implemented in the Irish specialised ILD centres.

A National Patient Charter for IPF was developed by the Irish Lung Fibrosis Association (ILFA) and launched in 2015. It calls for early and accurate diagnosis, access to treatment and support services for patients.

In addition, the Irish Thoracic Society created an Interstitial Lung Group that set up a National Patient Registry to record the incidence of and clinical data on patients with IPF in Ireland. This spans all the hospital groups with most specialised centres actively participating.

Key challenge: Early diagnosis remains the main challenge. More awareness of IPF is needed, especially at a primary care level to recognise the features of IPF and stimulate referrals.

Diagnostic procedures for IPF are standardised and IPF guidelines seem to be well implemented within the centres with specialist interest in ILD, where multidisciplinary teams are in place (an IPF multidisciplinary care pathway is included in the ITS statement on IPF). These centres are well distributed across the country and they work in collaboration with other hospitals regionally and with primary care providers.

Upon diagnosis, information leaflets and printed materials are available for patients from some healthcare professionals and ILFA. IPF self-management is also considered an integral part of IPF care.

Key challenge: Ensuring patients are referred in a timely manner to an ILD specialised centre to facilitate prompt access to pharmacological treatment remains a concern.

The two EMA-approved pharmacological treatments for IPF are available and reimbursed with no out-of-pocket costs to patients in Ireland (only if a patient has a medical card). The pharmacological treatments can be prescribed by respiratory physicians and the prescription can be renewed by general practitioners. The antifibrotic treatments are dispensed by community pharmacies.

Key challenge: Pulmonary rehabilitation programmes are available but only in some hospitals, and they do not specifically target IPF patients.

Non-pharmacological treatment options are available to IPF patients and costs are reimbursed (only if a patient has a medical card).

Oxygen therapy at home or in hospital is available to patients with a doctor’s prescription. Oxygen therapy for patients admitted to hospital is provided for free while the cost of home oxygen is fully reimbursed only if a patient has a medical card. Partial reimbursement to cover the increased electricity costs associated with using oxygen therapy is not standardised and it depends on regional/local health budgets. Pulmonary rehabilitation programmes are also available in some hospitals and in the community. However, it appears that at present the majority of pulmonary rehabilitation services target patients with Chronic Obstructive Pulmonary Disease (COPD), therefore there is a clear need to expand resources to include more patients with IPF.

Lung transplantation and clinical trials are also available to IPF patients.

Palliative care is available to IPF patients across all settings (community, hospital and hospice) and it is fully reimbursed.

In the overall patient journey, the family, the respiratory physicians, the nurses, the patient organisation and the support groups provide relevant support to IPF patients and their families.

Patient representative statement

“While it appears that Ireland is performing well in some indicators, IPF care could be better. National healthcare policies, education and awareness activities and healthcare investment are needed to improve the IPF clinical care pathway and to ensure patients have access to an early and accurate diagnosis and treatments, and that healthcare professionals are optimally resourced. ILFA and the Irish Thoracic Society will continue to lobby for improved resources and an ILD clinical care programme.”

Nicola Cassidy, Irish Lung Fibrosis Association
General introduction and guidelines

A Position Paper on the diagnosis and management of IPF was adopted in 2015 by the Italian Association of Hospital Pulmonologists (Associazione Italiana Pneumologi Ospedalieri, AIPO) and the Italian Medical Respiratory Society (Società Italiana Medicina Respiratoria, SIMeR). As the organisation and delivery of healthcare services are a competence of the Italian Regions, regional IPF care pathways are not available in all regions.

The very last version of the 2018 ATS/ERS/JRS/ALAT international IPF guidelines has not been translated, and these guidelines are not always correctly implemented across all the specialised centres.

The Italian Ministry of Health regularly updates a List of Rare Diseases that are covered by the National Health System. IPF was included in the List in 2017.

Diagnosis and access to specialised care

**Key challenge:** Delayed diagnosis and late referral to the specialised centres have been reported as the main challenges in Italy.

The diagnostic procedure is not standardised and it might differ between regions, leading to different quality of care. Specialised ILD centres are available across the entire territory and are listed in the IPF Centres Guide (Observatory of Rare Diseases, Osservatorio Malattie Rare). Multidisciplinary discussions take place in these centres with the objective of achieving a correct diagnosis. Late diagnosis remains an issue as not all IPF patients are referred to the specialised centres in a timely manner. Although they are critical support system for patients and carers, there are shortages and lack of recognition of specialist ILD nurses. Upon diagnosis, information materials are available for patients, mainly provided by the local patient support groups.

Access to pharmacological treatment

**Key challenge:** Prescribing centers are identified at a regional level and the number of centers might differ a lot from one region to another one ranging from 1 or 2 centers per region to 20 centers per region.

EMA-approved IPF pharmacological treatments are available and reimbursed with no out-of-pockets costs to Italian patients. The pharmacological treatments are prescribed by specialist respiratory physicians (as allowed by the regional Health System) and treatment is only provided through hospital pharmacies.

Access to non-pharmacological treatment

**Key challenge:** Inequalities persist between regions when it comes to access to non-pharmacological treatments, in particular re. oxygen therapy (different supply valves that can limit patient mobility) and pulmonary rehabilitation (only reimbursed in hospital)

Non-pharmacological treatment options are not always available to IPF patients in Italy and the costs associated with these treatments are not always fully reimbursed.

Oxygen therapy is available and reimbursed both in hospital and at home. The main issue is that different regions provide different supply valves for the oxygen concentrators affecting patients’ in-country mobility.

Pulmonary rehabilitation – when available – is only reimbursed when it is performed in hospital. Private centres providing rehabilitation exist but the patients have to bear all the costs. Huge discrepancies among the regions have also been reported, with the biggest difference between the North and the South of the country.

Lung transplantations are performed in Italy but donor availability and long waiting times (up to two years) can represent serious barriers.

IPF patients have access to clinical trials although retrieving information about it might be difficult at times.

Access to palliative care and end-of-life care

**Key challenge:** Palliative care is not always available for IPF patients in Italy

Palliative care is not always available to IPF patients in Italy but when it is made available, it is covered by the National Healthcare System. Priority is given to terminaly ill patients and access to patients with other diseases might be very difficult.

For end-of-life care, only private hospices are available and the costs can be quite high.

In the overall patient journey, the respiratory physician, the family and the local support groups are the ones providing relevant support to IPF patients.

HCP statement

“Delayed diagnosis and late referral to the specialised centres are two of the main issues affecting IPF patients in Italy. Patients with suspected IPF should promptly be referred to an ILD specialised centre. Through a team of different professionals who are experts in the field, the patient could possibly avoid invasive procedures and have a correct diagnosis, which is the starting point for the proper management of IPF and a better quality of life.”

Elisabetta Balestro, University of Padova
General introduction and guidelines

The ATS/ERS/URS/ALAT international IPF guidelines are implemented in Poland and Polish national guidelines are in development. However, there are no IPF care pathways. There is no official list of rare diseases.

Diagnosis and access to specialised care

**Key challenge:** There are no specialised ILD centres in Poland.

There are no official ILD centres in Poland but respiratory physicians are available in hospital. Multidisciplinary teams are also not widely available and in some hospitals there are no ILD nurses who can support patients with the daily management of the disease.

Upon diagnosis, information materials are available for patients, usually provided by the patient support groups.

Access to pharmacological treatment

**Key challenge:** Only some hospitals are allowed to prescribe the pharmacological treatments, and those who can have a set reimbursement capacity which can hinder access to treatment.

EMA-approved pharmacological treatments for IPF are available and reimbursed with no out-of pockets costs to patients. However, in some of the biggest hospitals, where the number of patients exceeds the reimbursement capacity, there is a waiting list to get pharmacological treatment. The pharmacological treatments can be prescribed by respiratory physicians in hospitals that are authorised to prescribe them; the treatment is only provided through hospital pharmacies.

Access to non-pharmacological treatment

**Key challenge:** Access to non-pharmacological treatments is not optimal in Poland. There are limitations and long waiting times to access oxygen therapy, pulmonary rehabilitation and lung transplantation.

Non-pharmacological treatment options are available to IPF patients in Poland but the costs associated with these treatments are not always fully reimbursed. Oxygen therapy is reimbursed when delivered in the hospital and at home (via home oxygen concentrators) but the waiting times can be very long; portable oxygen supply devices are not reimbursed. Pulmonary rehabilitation programmes are available only in hospitals and the cost is covered by the national healthcare system; however waiting times might be long. Pulmonary rehabilitation is also delivered privately but it is not reimbursed. There are very few transplantation centres in Poland which means that although lung transplantation is available to IPF patients, in reality waiting times are very long and access is limited. IPF patients in Poland have access to clinical trials.

Access to palliative care and end-of-life care

**Key challenge:** There is no dedicated palliative care service targeted to IPF patients.

Palliative care is mainly delivered to oncology patients and it is reimbursed by the national healthcare system when it is performed in hospital and at home. Both private and public hospices exist.

In the overall patient journey, the respiratory physician and the local patient support groups are the ones providing relevant support to IPF patients.

HCP statement

“Although both antifibrotic drugs are available to Polish patients, resources and funding are still not sufficient to provide them right after diagnosis. The lack of officially-recognised specialised ILD centres is also an issue that affects timely diagnosis and access to treatment. Additional issues are insufficient oxygen supply and poor access to rehabilitation centres, given the long waiting lists. On a positive side, over the past few years both healthcare professionals and patients have acquired significant knowledge about the disease.”

Katarzyna Lewandowska, National Tuberculosis and Lung Diseases Research Institute Warsaw
Romania has national IPF guidelines for healthcare professionals, who also rely on international guidelines (ATS/ERS/RS/ALAT). The national guidelines were developed by the Romanian Society of Pneumology in 2015. Although they are not officially recognised through a ministerial order, these national guidelines are implemented by healthcare centres and serve as a reference point for all Romanian healthcare professionals.

Romania had a National Rare Diseases Plan between 2010-2014. The National Healthcare Strategy 2014-2020 has a section dedicated to rare diseases and it is foreseen that a new plan will be developed in the future. Furthermore, the National Health Insurance body (Casa Nationala de Asigurari de Sanatate) House is running the National Programme for Rare Diseases, which sets the criteria for the reimbursement of rare diseases treatment. IPF is included in the list of diseases eligible for reimbursement.

**Diagnosis and access to specialised care**

**Key challenge:** The lack of general IPF awareness among general practitioners and primary care physicians is leading to delayed specialist referrals and diagnosis.

There are 5 main centres in Romania treating IPF and ILD patients (in Bucharest, Cluj, Constanta, Iasi and Timisoara), but they are not officially recognised as ILD expert centres. Multidisciplinary teams are available in these centres.

There are no standardised diagnostic procedures and no established IPF patient pathways in Romania. This leads to regional differences in quality of care. Late diagnosis remains an issue as not all IPF patients are referred to the specialised centres in a timely manner. This is mainly because general practitioners and primary care physicians have a limited knowledge of IPF.

Upon diagnosis, no information materials are available for patients.

**Access to pharmacological treatment**

**Key challenge:** Early diagnosis and timely referral to a respiratory specialist would ensure faster access to pharmacological treatment.

The two EMA-approved pharmacological treatments for IPF are available and reimbursed with no out-of pockets costs in Romania.

The pharmacological treatments can be prescribed by any respiratory physician and are dispensed by community pharmacies. Nevertheless, the lack of disease awareness results in treatment access delays.

**Access to non-pharmacological treatment**

**Key challenge:** The cost of oxygen at home is only partially reimbursed by the national healthcare system and ambulatory oxygen is not reimbursed at all.

Non-pharmacological treatment options are available to IPF patients in Romania but the costs associated with these treatments are not always fully reimbursed.

Oxygen therapy is partially reimbursed when delivered at home, but there is no reimbursement for portable oxygen supply devices, which are available at very high costs.

Pulmonary rehabilitation programmes are available in a limited number of centres (in Bucharest, Timisoara and Iasi). In Bucharest, rehabilitation programmes are delivered in an ambulatory setting, while in Timisoara and Iasi, they are available in a hospital setting. The cost is fully covered by the national healthcare system.

There is only one transplantation centre in Romania where lung transplantsations are performed. Donor availability could represent another serious barrier.

There are great delays in the approval process of clinical trials in Romania, as a result access to trials seems to be problematic for IPF patients.

**Access to palliative care and end-of-life care**

**Key challenge:** There is no dedicated palliative care service targeted to IPF patients.

Palliative care is offered only in a few hospitals in the country. Home hospice is not a viable option for patients.

Families and respiratory physicians are the ones providing relevant support to IPF patients. IPF has a huge impact on family members acting as the patient carer; there is a significant loss in terms of productivity at work for these relatives who would need to quit their job to take care of the patients.

**HCP statement**

“Severe underdiagnosis is currently the main problem for IPF in Romania. More efforts are needed to increase awareness about IPF and interstitial lung diseases among general practitioners and internal medicine specialists, so that patients can be referred to the expert centres for accurate diagnosis and treatment as early as possible. The official recognition of expert centres, better communication between clinicians and radiologists, and availability of portable oxygen devices are also priorities.”

*Dr Irina Strâmbu, Marius Nasta Pneumophtisiology Institute*
Spain follows the ATS/ERS/JRS/ALAT international IPF guidelines and has developed national guidelines for diagnosis and treatment of IPF, which have been updated in 2017. Promoting the harmonised implementation of IPF guidelines all over Spain remains a priority.

Spain has a "National Strategy for Rare Diseases"; but it does not include an implementation plan with dedicated budget. The central government has allocated some funding for the research and development of medicines for rare diseases.

**General introduction and guidelines**

Spain follows the ATS/ERS/JRS/ALAT international IPF guidelines and has developed national guidelines for diagnosis and treatment of IPF, which have been updated in 2017. Promoting the harmonised implementation of IPF guidelines all over Spain remains a priority.

Spain has a "National Strategy for Rare Diseases"; but it does not include an implementation plan with dedicated budget. The central government has allocated some funding for the research and development of medicines for rare diseases.

**Diagnosis and access to specialised care**

Not all Spanish regions have an ILD Unit with standardised procedures for IPF diagnosis and care. A peculiarity of the Spanish healthcare system is that the existing specialised ILD Units lack governmental accreditation (named CSUR), preventing them from participating as 'full members' in the European Rare Networks for rare diseases (such as ERN-LUNG).

This situation creates access inequality amongst Spanish patients. This fragmented approach also applies to referral procedures from primary care to specialised centres.

Raising awareness of IPF among radiologists and primary care physicians remains a priority in order to improve timely diagnosis and access to specialised care.

**Key challenge:** Existing ILD units lack formal recognition as reference centres and are not available in all regions, creating inequalities between patients, and delays in referral and diagnosis of IPF.

**Access to pharmacological treatment**

The two EMA-approved treatments are available and fully reimbursed in Spain. As budget for orphan drugs is limited, the progression of the disease also plays a role when it comes to granting access to pharmacological treatment, thus creating delays and limiting access.

The pharmacological treatments can be prescribed by respiratory physicians and are only dispensed by hospital pharmacies.

**Key challenge:** Inequality in access to pharmacological treatment amongst Spanish regions is a major challenge as different regional governments may allocate different budgets to rare diseases.

**Access to non-pharmacological treatment**

When it comes to non-pharmacological treatments, oxygen therapy both outpatient and inpatient, is reimbursed, under the condition that it is prescribed by a respiratory physician.

Pulmonary rehabilitation is mainly offered to COPD (chronic obstructive pulmonary disease) patients, and it is open to IPF patients only in a few centres. Even when available, pulmonary rehabilitation is fully reimbursed only for a period of 4 months.

The Spanish transplant programme is the best supported procedure in the Spanish healthcare system.

**Key challenge:** Access to pulmonary rehabilitation is too limited, geographically and in time.

**Access to palliative care and end-of-life care**

When it comes to non-pharmacological treatments, oxygen therapy both outpatient and inpatient, is reimbursed, under the condition that it is prescribed by a respiratory physician.

Pulmonary rehabilitation is mainly offered to COPD (chronic obstructive pulmonary disease) patients, and it is open to IPF patients only in a few centres. Even when available, pulmonary rehabilitation is fully reimbursed only for a period of 4 months.

The Spanish transplant programme is the best supported procedure in the Spanish healthcare system.

**Key challenge:** Lack of connection between ILD units and palliative care teams means that IPF patients have very unequal access to palliative and end-of-life support.

There are inequalities in access to palliative and end-of-life care across the Spanish regions, since there is no official circuit between ILD Units and palliative care teams. Access is granted on the basis of individual initiatives of some ILD Units.

The patient’s right to die at home is granted at the initiative of individual centres.

**Patient representative statement**

"In Spain it is necessary to improve early diagnosis of IPF. It is also necessary to create specific Multidisciplinary Centres that would allow an adequate follow-up and treatment to those suffering from the disease."

Carlos Lines Millán, Asociación de Familiares y Enfermos de Fibrosis Pulmonar Idiopática
In the Netherlands, there is no official list of rare diseases. Experts refer to the Orphanet list of rare diseases, which includes IPF. The ATS/ERS/JRS/ALAT international IPF guidelines are correctly implemented. The Dutch Pulmonologists Society has adopted a position paper that endorses most of the recommendations from the international guidelines. The document is not available in the public domain.

**Diagnosis and access to specialised care**

**Key challenge:** Late diagnosis has been reported as the main challenge. Raising awareness of IPF among general practitioners is considered to be one of the first steps towards timely diagnosis.

There are three officially acknowledged ILD/IPF specialised centres in The Netherlands: the Erasmus University Medical Centre in Rotterdam (ILD/IPF), the St. Antonius Ziekenhuis in Nieuwegein (ILD/IPF) and the Onze Lieve Vrouwen Gasthuis in Amsterdam (IPF). Furthermore, a network of treatment centres working in close collaboration with the abovementioned specialised centres exists. It aims to provide expert care for patients closer to their home. This network connects with the specialised centres through multidisciplinary team meetings taking place via teleconference.

In all these centres, IPF guidelines are properly implemented and the diagnostic procedure for IPF has also been reported to be standardised. In 2018 a vision document describing the current status of care and unmet needs of IPF patients was developed by the Erasmus Medical Center in Rotterdam with the support of Longfibrose Patiëntenvereniging, the Dutch IPF patient group. On the basis of this document, there are ongoing projects aimed at aligning IPF care pathways in the Netherlands.

Upon diagnosis, information materials provided by the local patient support groups and by the specialised centres are available to patients.

**Access to pharmacological treatment**

**Key challenge:** Late referral to specialised centres has been flagged as one of the main barriers to prompt access to pharmacological treatment.

EMA-approved pharmacological treatments for IPF are available and reimbursed with no out-of pockets costs to patients. The pharmacological treatments can be prescribed by the specialised centres and they are dispensed by the community pharmacies.

**Access to non-pharmacological treatment**

Non-pharmacological treatment options are available to IPF patients in the Netherlands and the costs associated with these treatments are reimbursed.

Oxygen therapy at home and in hospital is available to patients and is fully covered by the national healthcare system. Pulmonary rehabilitation programmes have been developed but are not always widely available across the country.

Lung transplantation is an option for patients, however the general health condition could represent a barrier to this procedure. IPF patients in The Netherlands have access to clinical trials.

**Access to palliative care and end-of-life care**

**Key challenge:** The delivery of palliative care is not always optimal as there is a lack of awareness on the needs of IPF patients. Additionally, palliative care is too often confused with end-of-life care, without necessarily looking at optimising quality of life.

Palliative care is available and normally delivered either in the hospital or in local settings. However lack of awareness of palliative care among IPF patients, as well as confusion with end-of-life care means that it is not optimally organised and delivered.

In the overall patient journey, the respiratory physician, the ILD specialised nurse and the patient support groups are the ones providing support to the IPF patients and their families.

**Patient representative statement**

“Late diagnosis remains the main issue in the Netherlands. Increasing knowledge and improving understanding of the disease among the general population and primary care providers are two of the main goals of the Dutch IPF patient organisation. This can facilitate early diagnosis and ultimately contribute to better access to pharmacological treatment.

Patient support groups play a key role in supporting the patients and their families after diagnosis; we believe this is very important for the everyday management of the disease and to improve the quality of life of patients living with IPF.”

Harry Van Den Haak, Longfibrose Patiëntenvereniging
Diagnosis and access to specialised care

The diagnostic process for IPF is standardised in the specialised centres, where there is access to a specialist multidisciplinary team. Currently, there are 23 specialist-prescribing centres in England, located in all major cities. However, in Wales, Scotland and Northern Ireland a slightly different structure exists where there are regional hospitals with ILD expertise. ILD specialist nurses are available to support and advise patients on the everyday management of the disease, representing a significant advantage for patients. Delayed referrals from primary to secondary or on to specialist ILD care are still problematic and lead to misdiagnosis, delays in diagnosis and access to treatment. Upon diagnosis, informative materials are available for patients; these are provided by clinical nurse specialists and patient support groups.

Key challenge: Patients with FVC>80% are currently excluded from treatment based upon NICE guidance giving rise to inequalities in access to pharmacological treatment in the UK.

Access to pharmacological treatment

EMA-approved pharmacological treatments for IPF are available in the UK and NICE national guidelines are in place for pharmacological treatment:

- **NICE guidelines TA054**: Pirfenidone for treating idiopathic pulmonary fibrosis.
- **NICE guidelines TA379**: Nintedanib for treating idiopathic pulmonary fibrosis.

The pharmacological treatments are reimbursed with no out-of-pocket costs for patients who are eligible to receive anti-fibrotic therapy. They can be prescribed by the specialised centres and can be delivered directly to the patient's home. Of note, in England, NICE limits access to the anti-fibrotic therapies. Patients whose FVC is outside of the treatment range are currently not eligible to receive NHS funded anti-fibrotic therapy.

Key challenge: IPF patients are not always being referred to specialised centres by general hospitals in a timely manner.

Access to non-pharmacological treatment

NICE guidelines giving rise to inequalities in access to pharmacological treatment in the UK.

Key challenge: Pulmonary rehabilitation programmes are available but remain generic and not specifically adapted to the needs of IPF patients.

Non-pharmacological treatment options are available to IPF patients in the UK. Oxygen is delivered to the patient's home and pulmonary rehabilitation is predominantly provided in the patient's local hospital or at ambulatory level. However, pulmonary rehabilitation programmes are rarely specifically tailored to people with pulmonary fibrosis as they are generic programmes given to all patients with lung disease.

Non-pharmacological treatments are provided by the NHS, therefore there are no costs for patients other than travelling from home to hospital. Lung transplantation and clinical trials (which are usually run from the specialised centres) are also available to IPF patients meeting the designated criteria.

Key challenge: Patients may need to proactively ask for palliative and supportive care as it is not always embedded into the IPF treatment plan.

Palliative care is available to IPF patients at no additional cost. In the UK there are national guidelines in place for palliative and end-of-life care (Quality standard [QS13]). Patients can choose to receive palliative care in their preferred place of care, supported by specialist palliative care nurses and physicians. However, timely and local access to specialist palliative care is variable across the country.

In the overall patient journey, the family, respiratory physician, specialist nurses and patient groups are the primary support system for IPF patients and their families.

Access to palliative care and end-of-life care

The National Institute For Health And Care Excellence (NICE) clinical guidelines for diagnosis and management of IPF:

- **NICE quality standards** for IPF, which include chapters on diagnosis, the need for specialist nurses, oxygen therapy, pulmonary rehabilitation and palliative care;
- **National patient pathways** developed by NICE, specifically for IPF are also available and include a detailed flowchart on the patient care pathway, from diagnosis to management.

It is important to note that NICE guidelines were established in the UK to provide healthcare services; however, the incidence and the prevalence of IPF is now increasing in the UK. IPF is also mentioned in The British Thoracic Society Interstitial Lung Disease Registry Programme.

In addition, the United Kingdom has developed a strategy for rare diseases as well as an implementation plan – both endorsed by the Department of Health.

IPF Scorecard

The ATS/ERS/JRS/ALAT (International IPF) guidelines are available and the following national guidelines are also in place:

- **The National Institute For Health And Care Excellence** (NICE) clinical guidelines for diagnosis and management of IPF;
- **NICE quality standards** for IPF, which include chapters on diagnosis, the need for specialist nurses, oxygen therapy, pulmonary rehabilitation and palliative care;
- **National patient pathways** developed by NICE, specifically for IPF are also available and include a detailed flowchart on the patient care pathway, from diagnosis to management.

HCP statement

"There is a great need for standardised patient pathways to enable earlier diagnosis and timely referral to specialised ILD centres. The rate that IPF progresses is very variable and unpredictable. There are no biomarkers that are currently able to identify those people at risk of more rapidly progressive disease and who may benefit from earlier treatment interventions. It is hoped that an improved understanding of the genetics and disease pathogenesis will lead to a precision medicine approach whereby disease modifying treatments are tailored to an individual patient according to their specific genes and molecular signature."

Helen Parfrey, Papworth Hospital
Acknowledgements

The EU-IPFF would like to thank all the patients, carers and healthcare professionals who contributed to this Report by sharing their professional and personal experiences. In particular, we would like to thank the following patient organisations:

LOT Austria (AT)
Lungenfibrose Forum Austria (AT)
Association Belge contre la Fibrose Pulmonaire Idiopathique (BE)
Belgische vereniging voor longfibrose (BE)
IPF Bulgaria (BG)
Udruga Jedra (HR)
Hengitysliitto (FI)
Association Pierre Enjalran Fibrose Pulmonaire Idiopathique (FR)
Lungenfibrose e.V. (DE)
Hellenic Pulmonary Fibrosis Association (GR)
Magyar Tüdőfibrózis Egyesület (HU)
Irish Lung Fibrosis Association (IE)
AMA Fuori dal Buio (IT)
FIMARP (IT)
Longfibrose Patiëntenvereniging (NL)
IPF Polish Society (PL)
Asociatia pacientilor cu fibroza pulmonara idiopatica (RO)
Asociación de Familiares y Enfermos de Fibrosis Pulmonar Idiopática (ES)
Action for Pulmonary Fibrosis (UK)
British Lung Foundation (UK)
Pulmonary Fibrosis Trust (UK)

The EU-IPFF also wants to thank all its members and the members of the Scientific Advisory Board for their help in contributing to this Benchmarking Report and for their invaluable comments on earlier drafts.

The EU-IPFF is also grateful to Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche LTD and Galapagos NV who have financially supported the development of this Benchmarking Report, which was coordinated by Weber Shandwick.
Limitations

For the purpose of this Benchmarking Report:

- No differentiation was made in the severity of IPF (moderate, mild and severe cases);
- The sample of the study represents an inherent bias since it included only a limited number of countries and most of them are EU-IPFF member countries. Interviews took place over two years, with the first 13 countries surveyed in 2018 (Austria, Belgium, Bulgaria, France, Germany, Greece, Ireland, Italy, The Netherlands, Poland, Spain, United Kingdom and Hungary), and four additional countries surveyed between 2019 and 2020 (Croatia, Finland, Denmark and Romania);
- The responses provided by patient groups are accurate to the best of their knowledge, however they might be stemming from personal experiences or from experiences of other patients in each association;
- Some questions that were asked during the interviews have not been included in this short Report as not enough information on certain indicators was provided by the interviewees or responses varied too broadly and did not allow for comparison;
- Some patient representatives participated in phone interviews; for health-related reasons or for language-related reasons, some patient representatives filled in a written questionnaire instead;
- For one country, the scorecard was developed directly with a medical expert as no patient organisation exists.
- The replies were validated by the medical experts; however, the majority of them work in specialised ILD centres, which could affect their perception of IPF care in their country;
- The answers to the phone interviews were codified by interviewers; an interview guide was developed to minimise the personal bias but cannot fully eliminate it;
- When possible, the interviews were conducted in the native language of the respondent and then translated into English;
- The same colour code was used to assess different countries but does not necessarily mirror the same level of progression.
- A third party supplier translated the IPF national scorecard into the various national languages. Therefore, there may be slight differences from the original report in English.
- Each patient organisation had the opportunity to edit their national scorecard, which may result in differences from the scorecards in English.
The European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EU-IPFF) brings together eighteen European national patient associations from thirteen European countries. Its mission is to serve as the trusted resource for the IPF community by raising awareness, providing disease education, advancing care, and funding research. EU-IPFF collaborates with physicians, medical organisations, people with IPF, caregivers and policy-makers throughout Europe.

For further information, please visit www.eu-ipff.org.